BioPharmSignal logoBioPharmSignal

Company Profile

Molecular Partners Stock Price, News & Catalysts

Ticker:
MOLN
Exchange:
NASDAQ
Sector:
Biopharma
Location:
Switzerland

Stock performance

3.92 USD (-6.67%)

Close

Last updated: September 16, 2026

147M USD

Market cap

Why the stock is moving

Current closing-price context is not available for MOLN.

Company overview

DARPin Therapeutics Platform

Molecular Partners develops multi-specific protein medicines based on Designed Ankyrin Repeat Proteins, compact binding molecules that can be engineered for high affinity and modularity.

Radio-DARPins

The company is attaching therapeutic radioisotopes to DARPins to deliver radiation selectively to tumor targets while retaining flexibility across isotope payloads.

MP0712

MP0712 targets DLL3 and is being evaluated in small cell lung cancer and other DLL3-expressing neuroendocrine tumors.

Future catalysts

  • Initial Phase 1/2a clinical data for MP0712 are expected during 2026.
  • Molecular Partners expects to open a total of nine MP0712 clinical sites by year-end 2026.

Recent news

  1. 01

    Molecular Partners gibt Finanzergebnisse für das erste Halbjahr 2026 und wichtige Unternehmensentwicklungen bekannt: DLL3-Radiotherapie-Kandidat MP0712 erreicht in der Phase-1/2a-Studie die nächsthöhere Dosisstufe

  2. 02

    Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

  3. 03

    Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma

  4. 04

    Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

  5. 05

    Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

XLO

Xilio Therapeutics

CGON

CG Oncology, Inc.

GOVX

GeoVax Labs

IDYA

IDEAYA Biosciences

DCTH

Delcath Systems

ANGO

AngioDynamics

NKTR

Nektar Therapeutics

BLUE

bluebird bio, Inc.

Frequently Asked Questions

What is the current stock price of Molecular Partners (MOLN)?

Molecular Partners (MOLN) most recently closed at 3.92 USD, a -6.67% move versus the previous session.

What is the market cap of Molecular Partners (MOLN)?

Molecular Partners currently has a market capitalization of 147M USD on BioPharmSignal.

What does Molecular Partners do?

DARPin Therapeutics Platform Molecular Partners develops multi-specific protein medicines based on Designed Ankyrin Repeat Proteins, compact binding molecules that can be engineered for high affinity and modularity. Radio-DARPins The company is attaching therapeutic radioisotopes to DARPins to deliver radiation selectively to tumor targets while retaining...

On which exchange is MOLN stock listed?

Molecular Partners (MOLN) is associated with NASDAQ, Switzerland, Biopharma.

What is DARPin?

DARPin Therapeutics Platform Molecular Partners develops multi-specific protein medicines based on Designed Ankyrin Repeat Proteins, compact binding molecules that can be engineered for high affinity and modularity.

Which conditions is Molecular Partners targeting with DARPin?

Molecular Partners is associated with cancer therapeutics based on its company overview and current catalyst commentary.

How does Molecular Partners describe recent progress with DARPin?

Initial Phase 1/2a clinical data for MP0712 are expected during 2026. Molecular Partners expects to open a total of nine MP0712 clinical sites by year-end 2026.

What is Therapeutics?

DARPin Therapeutics Platform Molecular Partners develops multi-specific protein medicines based on Designed Ankyrin Repeat Proteins, compact binding molecules that can be engineered for high affinity and modularity.